Conserving fertility in the management of gynaecological cancers.
The quality of cancer treatment is judged by both morbidity and mortality. Patients benefit if morbidity is reduced without compromising mortality. This applies particularly for women who develop gynaecological malignancy during their childbearing years where curative treatment also renders them infertile. This study reviews the increasing role of fertility-sparing surgery in such women. A literature search was undertaken using PubMed, entering the terms endometrial cancer, cervical cancer and ovarian cancer in conjunction with the terms fertility and fertility sparing. Each relevant identified paper was reviewed, references checked and results collated to provide an evidence-based summary of fertility-sparing treatments for gynaecological malignancy. Fertility-sparing surgery is appropriate in many circumstances, and all doctors who advise young women with gynaecological malignancy should be aware of these possibilities. However, data are relatively sparse in many situations, and careful counselling and balanced guidance are essential if patients are to understand the full implications of their choices.
Farthing
A
A
West London Gynaecological Cancer Centre, Queen Charlotte's Hospital, London, UK. a.farthing@imperial.ac.uk
D000328:Adult; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D002584:Cervix Uteri / Q000601:surgery; D005260:Female; D005833:Genital Neoplasms, Female / Q000628:therapy*; D006801:Humans; D007044:Hysterectomy / Q000379:methods; D007247:Infertility, Female / Q000517:prevention & control*
D018931:Antineoplastic Agents, Hormonal